Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing

BACKGROUND: Tumor mutational burden (TMB) has been investigated as a biomarker for immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene panel–based assays (as opposed to full exome sequencing) and different gene panels cover overlapping but distinct genomic coordi...

Descripción completa

Detalles Bibliográficos
Autores principales: Anaya, Jordan, Sidhom, John-William, Cummings, Craig A., Baras, Alexander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044680/
https://www.ncbi.nlm.nih.gov/pubmed/36999044
http://dx.doi.org/10.1158/2767-9764.CRC-22-0339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044680/
https://www.ncbi.nlm.nih.gov/pubmed/36999044
http://dx.doi.org/10.1158/2767-9764.CRC-22-0339

Ejemplares similares